Subcutaneous Immunization with Unaltered Axenic Malaria Parasite Liver Stages Induces Sterile Protection Against Infectious Sporozoite Challenge

Overview

Journal Vaccines (Basel)

Date 2022 Nov 11

PMID 36366392

Authors

Mohd Kamil

Gozde Deveci

Umit Y Kina

Stefan H I Kappe

Ahmed S I Aly

Affiliations

Soon will be listed here.

Abstract

Host cell-free, axenic development of liver stages (LS) of the malaria parasite has been demonstrated. Here we explored axenic liver stages as a novel live whole parasite malaria vaccine platform, which is unaltered and not prone to human-error, compared to the immunization with live-attenuated sporozoites that must be done intravenously. We show that in contrast to live sporozoites, axenic LS are not infectious to the immunized host. Subcutaneous immunizations of mice with axenic LS, developed from wild-type (WT) sporozoites or WT sporozoites expressing enhanced-GFP, conferred sterile protection against infectious sporozoite challenge. Thus, axenic liver stages of and might constitute an attractive alternative to live sporozoite immunization.

References

Kaiser K, Camargo N, Kappe S . Transformation of sporozoites into early exoerythrocytic malaria parasites does not require host cells. J Exp Med. 2003; 197(8):1045-50. PMC: 2193875. DOI: 10.1084/jem.20022100. View

Aly A, Vaughan A, Kappe S . Malaria parasite development in the mosquito and infection of the mammalian host. Annu Rev Microbiol. 2009; 63:195-221. PMC: 2841446. DOI: 10.1146/annurev.micro.091208.073403. View

Zheng J, Pan H, Gu Y, Zuo X, Ran N, Yuan Y . Prospects for Malaria Vaccines: Pre-Erythrocytic Stages, Blood Stages, and Transmission-Blocking Stages. Biomed Res Int. 2019; 2019:9751471. PMC: 6794966. DOI: 10.1155/2019/9751471. View

Kaslow D . Malaria vaccine research & innovation: the intersection of IA2030 and zero malaria. NPJ Vaccines. 2020; 5(1):109. PMC: 7677906. DOI: 10.1038/s41541-020-00259-3. View

Vaughan A, Aly A, Kappe S . Malaria parasite pre-erythrocytic stage infection: gliding and hiding. Cell Host Microbe. 2008; 4(3):209-18. PMC: 2610487. DOI: 10.1016/j.chom.2008.08.010. View

Hoffman S, Goh L, Luke T, Schneider I, Le T, Doolan D . Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis. 2002; 185(8):1155-64. DOI: 10.1086/339409. View

Kreutzfeld O, Muller K, Matuschewski K . Engineering of Genetically Arrested Parasites (GAPs) For a Precision Malaria Vaccine. Front Cell Infect Microbiol. 2017; 7:198. PMC: 5450620. DOI: 10.3389/fcimb.2017.00198. View

Beeson J, Kurtovic L, Dobano C, Opi D, Chan J, Feng G . Challenges and strategies for developing efficacious and long-lasting malaria vaccines. Sci Transl Med. 2019; 11(474). DOI: 10.1126/scitranslmed.aau1458. View

Hart R, Lawres L, Fritzen E, Ben Mamoun C, Aly A . Plasmodium yoelii vitamin B5 pantothenate transporter candidate is essential for parasite transmission to the mosquito. Sci Rep. 2014; 4:5665. PMC: 4092334. DOI: 10.1038/srep05665. View

10.

Aly A, Deveci G, Yilmaz I, Abraham A, Golshan A, Hart R . Phenotypic Analysis of Rodent Malaria Parasite Asexual and Sexual Blood Stages and Mosquito Stages. J Vis Exp. 2019; (147). DOI: 10.3791/55688. View

11.

Duffy P, Gorres J . Malaria vaccines since 2000: progress, priorities, products. NPJ Vaccines. 2020; 5(1):48. PMC: 7283239. DOI: 10.1038/s41541-020-0196-3. View

12.

Seder R, Chang L, Enama M, Zephir K, Sarwar U, Gordon I . Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013; 341(6152):1359-65. DOI: 10.1126/science.1241800. View

13.

Silvie O, Semblat J, Franetich J, Hannoun L, Eling W, Mazier D . Effects of irradiation on Plasmodium falciparum sporozoite hepatic development: implications for the design of pre-erythrocytic malaria vaccines. Parasite Immunol. 2002; 24(4):221-3. DOI: 10.1046/j.1365-3024.2002.00450.x. View

14.

Kublin J, Mikolajczak S, Sack B, Fishbaugher M, Seilie A, Shelton L . Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects. Sci Transl Med. 2017; 9(371). DOI: 10.1126/scitranslmed.aad9099. View

15.

Mordmuller B, Surat G, Lagler H, Chakravarty S, Ishizuka A, Lalremruata A . Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature. 2017; 542(7642):445-449. PMC: 10906480. DOI: 10.1038/nature21060. View

16.

Lyke K, Ishizuka A, Berry A, Chakravarty S, DeZure A, Enama M . Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc Natl Acad Sci U S A. 2017; 114(10):2711-2716. PMC: 5347610. DOI: 10.1073/pnas.1615324114. View

17.

Molina-Franky J, Cuy-Chaparro L, Camargo A, Reyes C, Gomez M, Salamanca D . Plasmodium falciparum pre-erythrocytic stage vaccine development. Malar J. 2020; 19(1):56. PMC: 6998842. DOI: 10.1186/s12936-020-3141-z. View

18.

Reeder S, Reuschel E, Bah M, Yun K, Tursi N, Kim K . Synthetic DNA Vaccines Adjuvanted with pIL-33 Drive Liver-Localized T Cells and Provide Protection from Challenge in a Mouse Model. Vaccines (Basel). 2020; 8(1). PMC: 7157753. DOI: 10.3390/vaccines8010021. View

19.

Mendes A, Machado M, Goncalves-Rosa N, Reuling I, Foquet L, Marques C . A sporozoite-based vaccination platform against human malaria. NPJ Vaccines. 2018; 3:33. PMC: 6109154. DOI: 10.1038/s41541-018-0068-2. View

20.

Blasco B, Leroy D, Fidock D . Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. Nat Med. 2017; 23(8):917-928. PMC: 5747363. DOI: 10.1038/nm.4381. View